Medullary Thyroid Carcinoma
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour arising from parafollicular C cells that secretes calcitonin, representing 3–5% of thyroid cancers; 25% of cases are hereditary (MEN2A/2B or familial MTC).
This entry keeps the patient story, examination finding, previous reports and personal goal in one clinical frame rather than letting an online definition decide care; MTC diagnosis is supported by serum calcitonin (>100 pg/mL suspicious, >500 pg/mL highly likely) and CEA measurement; preoperative RET proto-oncogene mutation analysis is mandatory; this opening makes clear that a decision is not complete until physical examination, pathology or imaging when available, and the patient's overall health context are read together.
This assessment does not treat history as a simple symptom list; duration, location, change over time, speech, swallowing, breathing, pain, weight, voice quality and day-to-day effect are organized together; MTC does not respond to RAI; complete surgical resection is the only curative therapy; this structure keeps anxiety measured while making clinically important changes easier to describe during consultation.
Planning does not force the personal pathway into a single template; diagnostic certainty is considered first, functional expectation second, and risk or recovery burden after that; for the patient, the useful question is not the most aggressive option but the step that fits findings, reports and life priorities.
Counselling strengthens the patient file without turning internet reading into a personal diagnosis; previous notes, test results and reports are easier to interpret when arranged in one timeline; the consultation can then separate older information, new findings and details used mainly for comparison.
This content helps patients and relatives prepare better questions; it does not diagnose, choose a procedure or set personal timing by itself; safer conclusions come from combining this general frame with professional examination, current reports, patient goals and multidisciplinary assessment when the case calls for it.
Writing onset, side, pace of change and personal expectation in the same order keeps the story clearer.
Online information is used to organize better questions rather than turn reading into a personal conclusion.
If old reports, photographs, pathology text or medication lists exist, arranging them by date makes comparison easier.
Two patients may read the same topic while their personal stories differ, so broad statements stay limited and contextual.
Before discussion, the main worry, work or social impact and earlier experiences can be summarized in one paragraph.
The page bridges a short definition and the personal file; it gathers context without producing a final decision line.
Family observations around eating, speech, sleep or daily performance may help describe changes more concretely.
When reading this topic, separating the main concern, previous report wording and daily impact into short notes makes the visit easier to structure.
Additional reading for Medullary Thyroid Carcinoma keeps the patient's own wording and earlier document language visible side by side.
Additional reading for Medullary Thyroid Carcinoma keeps the patient's own wording and earlier document language visible side by side.
Additional reading for Medullary Thyroid Carcinoma keeps the patient's own wording and earlier document language visible side by side.
Additional reading for Medullary Thyroid Carcinoma keeps the patient's own wording and earlier document language visible side by side.
Additional reading for Medullary Thyroid Carcinoma keeps the patient's own wording and earlier document language visible side by side.
Bu rehberde
Diagnosis
Calcitonin >100 pg/mL raises strong suspicion for MTC; pentagastrin or calcium stimulation testing can unmask C-cell hyperplasia in small tumours. FNA calcitonin staining (90% sensitivity) and CEA immunoreactivity support the diagnosis. All newly diagnosed MTC patients must undergo germline RET mutation analysis and pheochromocytoma screening (24h urine or plasma free metanephrines). Beyond neck US, liver US or MRI and chest CT are recommended for metastasis workup.
Treatment
Standard surgery is total thyroidectomy with central neck dissection (Level VI); bilateral lateral dissection (Levels II–V) is added when calcitonin >500 pg/mL or lateral nodal disease is evident. Vandetanib 300 mg/day or cabozantinib 140 mg/day extend PFS in advanced disease (ZETA and EXAM trials). Next-generation RET-selective inhibitors (selpercatinib, pralsetinib) show superior efficacy and tolerability in RET-mutant MTC.
When to Seek Care
All first-degree relatives of MTC or MEN2 patients should be referred for RET mutation testing to a genetic oncology or endocrinology clinic. A painful neck mass, elevated calcitonin, or the combination of abdominal pain and hypertension (suggesting pheochromocytoma) requires urgent evaluation.
Frequently asked questions
What does it mean?
When is it clinically important?
What information helps the visit?
Does this page make personal decisions?
Bu tedavi hakkında daha fazla bilgi edinin
Prof. Dr. Özdoğan kliniğinden detaylı rehber
References
Bu sözlük maddesi yalnızca bilgilendirme amaçlıdır ve tıbbi tavsiye niteliği taşımaz. Tanı ve tedavi için uzman bir doktora başvurunuz.